Industry Briefs: Apr. 2, 2012

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Apr 05, 2012
By PharmTech Editors

Company News

Albany Molecular Research has agreed to license to Bessor Pharma its tubulin-inhibitor program for treating cancer. Read More

A federal district court has ruled in favor of AstraZeneca on its formulation patent for Seroquel (quetiapine fumarate) extended-release tablets. Read More

BioStorage Technologies has expanded its services in the academic research sector throughout the northeast United States. Read More

Eisai and Minophagen Pharmaceutical have concluded a license agreement concerning the development and commercialization of the cutaneous T-cell lymphoma treatment bexarotene. Read More

Gerresheimer has acquired Neutral Glass. Read More

GlaxoSmithKline has agreed to purchase 10 million shares to increase its ownership in Theravance. Read More

Illumina’s board of directors has unanimously rejected Roche’s revised offer to acquire the company for $51 per share in cash. Read More

Pharmaceutical Research and Manufacturers of America has issued a statement to support the National Governor’s Association’s Prescription Drug Abuse Reduction Policy Academy. Read More

Sigma Aldrich has acquired Research Organics. Read More

People News

Laureate Biopharma has named Lisa Cozza as vice-president of business development. Read More

Merck has appointed Michael J. Holston as chief ethics and compliance officer, effective June 25, 2012. He will succeed Richard S. Bowles, who plans to retire from the company. Read More